Long Focus Capital Management, LLC Adaptimmune Therapeutics PLC Transaction History

Long Focus Capital Management, LLC

$2.88 Billion
Q1 2025

A detailed history of Long Focus Capital Management, LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Long Focus Capital Management, LLC holds 23,756,687 shares of ADAP stock, worth $6.41 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

23,756,687

Previous 20,494,393 15.92%

Holding current value

$6.41 Million

Previous $11.1 Million 57.07%

% of portfolio

0.16%

Previous 0.38%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.2 - $0.65 $652,458 - $2.12 Million	3,262,294 Added 15.92%	23,756,687 $4.75 Million
Q4 2024 Feb 14, 2025	BUY	$0.54 - $0.95 $3.89 Million - $6.83 Million	7,194,503 Added 54.09%	20,494,393 $11.1 Million
Q3 2024 Nov 13, 2024	BUY	$0.92 - $1.39 $877,195 - $1.33 Million	953,473 Added 7.72%	13,299,890 $12.6 Million
Q2 2024 Aug 13, 2024	BUY	$0.83 - $1.47 $1.38 Million - $2.44 Million	1,662,184 Added 15.56%	12,346,417 $12.1 Million
Q1 2024 May 14, 2024	SELL	$0.7 - $1.75 $981,877 - $2.45 Million	-1,402,682 Reduced 11.6%	10,684,233 $16.9 Million
Q4 2023 Feb 14, 2024	BUY	$0.43 - $0.79 $483,215 - $887,768	1,123,757 Added 10.25%	12,086,915 $9.55 Million
Q3 2023 Nov 14, 2023	BUY	$0.73 - $1.04 $2.3 Million - $3.28 Million	3,150,630 Added 40.33%	10,963,158 $8.55 Million
Q2 2023 Aug 14, 2023	BUY	$0.9 - $1.51 $2.14 Million - $3.59 Million	2,377,089 Added 43.73%	7,812,528 $7.19 Million
Q1 2023 May 17, 2023	BUY	$1.06 - $2.16 $2.82 Million - $5.75 Million	2,662,648 Added 96.03%	5,435,439 $5.92 Million
Q1 2023 May 12, 2023	SELL	$1.06 - $2.16 $2.66 Million - $5.42 Million	-2,510,848 Reduced 47.52%	2,772,791 $3.02 Million
Q4 2022 Feb 13, 2023	BUY	$1.05 - $2.53 $518,856 - $1.25 Million	494,149 Added 10.32%	5,283,639 $7.71 Million
Q3 2022 Nov 14, 2022	BUY	$1.06 - $2.41 $116,598 - $265,097	109,999 Added 2.35%	4,789,490 $5.15 Million
Q2 2022 Aug 12, 2022	BUY	$1.33 - $2.28 $332,500 - $570,000	250,000 Added 5.64%	4,679,491 $7.96 Million
Q1 2022 May 13, 2022	BUY	$1.73 - $4.06 $3.92 Million - $9.2 Million	2,267,178 Added 104.85%	4,429,491 $9.13 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $5.68 $7.57 Million - $12.3 Million	2,162,313 New	2,162,313 $8.11 Million

Others Institutions Holding ADAP

# of Institutions

Shares Held

113M

Call Options Held

77.5K

Put Options Held

14.2K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $44.1M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Long Focus Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Long Focus Capital Management, LLC with notifications on news.

Account

Long Focus Capital Management, LLC Adaptimmune Therapeutics PLC Transaction History